#### **CLEARBRIDGE HEALTH LIMITED**

(Company Registration No.: 201001436C) (Incorporated in the Republic of Singapore)

# RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 1,279,125,560 NEW ORDINARY SHARES IN THE CAPITAL OF CLEARBRIDGE HEALTH LIMITED ("RIGHTS ISSUE")

- RESULTS OF THE RIGHTS ISSUE
- RESULTS OF THE IRREVOCABLE UNDERTAKINGS
- REFUND FOR INVALID OR UNSUCCESSFUL ACCEPTANCES AND EXCESS APPLICATIONS, AND OF SURPLUS APPLICATION MONIES
- FINAL NET PROCEEDS FROM THE RIGHTS ISSUE
- LISTING AND QUOTATION OF THE RIGHTS SHARES

# 1. Introduction

- 1.1 The board of directors (the "Board" or "Directors") of Clearbridge Health Limited (the "Company", and together with its subsidiaries, the "Group") refers to (i) the Company's announcements dated 27 September 2024, 7 October 2024, 16 October 2024, 23 October 2024, 28 October 2024, 7 November 2024, 19 November 2024, 20 November 2024 and 22 November 2024 in relation to the Rights Issue; (ii) the Company's offer information statement dated 19 November 2024 in relation to the Rights Issue, which was electronically disseminated by the Company on 19 November 2024 (the "Offer Information Statement"); and (iii) the first corrigendum and the second corrigendum to the Offer Information Statement released on SGXNet on 20 November 2024 and 22 November 2024 respectively.
- 1.2 Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Offer Information Statement.

# 2. Results of the Rights Issue

# 2.1 Level of subscription

Based on the total number of issued and paid-up shares in the capital of the Company (excluding Treasury Shares and Subsidiary Holdings) of 619,741,352 Shares as at the Record Date, a total of 1,239,482,704 Rights Shares were available for subscription under the Rights Issue.

The Company is pleased to announce that, as at the close of the Rights Issue on 4 December 2024, valid acceptances and valid Excess Applications were received for a total of 2,042,296,338 Rights Shares, representing approximately 164.8% of the 1,239,482,704 Rights Shares available for subscription under the Rights Issue. This includes valid acceptances and valid Excess Applications for a total of 382,425,654 Rights Shares received from the Undertaking Shareholders in accordance with the Irrevocable Undertakings, and a valid Excess Application for an additional 300,000,000 Rights Shares by LSHL.

Details of the valid acceptances and valid Excess Applications received for the Rights Shares under the Rights Issue are as follows:

	Number of Rights Shares	As a percentage of the total number of Rights Shares available for subscription under the Rights Issue (1)
Valid acceptances	642,730,714	51.9%
•	, ,	31.970
Valid Excess Applications	1,399,565,624	112.9%
Total	2,042,296,338	164.8%

#### Note:

Applicants with valid acceptances of their provisional allotment of Rights Shares will be allocated in full for such acceptances.

# 2.2 Excess Applications

A total of 596,751,990 provisional allotments of Rights Shares (including unsold "nil-paid" provisional allotments of Rights Shares of Foreign Shareholders and fractional entitlements which were disregarded in arriving at the Entitled Shareholders' provisional allotments of Rights Shares) which were not accepted or validly taken up by or allotted to Entitled Shareholders, Renouncees and Purchasers will be allocated to satisfy the valid Excess Applications.

In compliance with the Catalist Rules, in the allotment of Excess Rights Shares, preference was given to Shareholders for the rounding of odd lots, and Directors and Substantial Shareholders (including the Undertaking Shareholders) who have Control or influence over the Company in connection with the day-to-day affairs of the Company or the terms of the Rights Issue, or have representation (direct or through a nominee) on the Board, ranked last in priority for the rounding of odd lots and allotment of Excess Rights Shares. No Excess Rights Shares will be allotted which would result in a transfer of Controlling Interest in the Company unless otherwise approved by Shareholders in a general meeting.

# 2.3 Allotment and crediting of the Rights Shares

In the case of Entitled Depositors, Entitled Scripholders (who have furnished valid Securities Account numbers in the relevant form comprised in the PAL) and their Renouncees, with valid acceptances of their provisional allotment of Rights Shares and/or successful Excess Applications, share certificate(s) representing such number of Rights Shares will be sent to CDP within ten (10) Market Days after the Closing Date, and CDP will thereafter credit such number of Rights Shares to their relevant Securities Accounts. CDP will then send a notification letter to the relevant Shareholders stating the number of Rights Shares that have been credited to their Securities Accounts. The Rights Shares are expected to be credited to the relevant Shareholders' respective Securities Accounts on or around 12 December 2024.

In the case of Entitled Scripholders and their Renouncees with valid acceptances of their provisional allotment of Rights Shares and/or successful Excess Applications and who have, among others, failed to furnish or furnished incorrect or invalid Securities Account numbers in the relevant form comprised in the PAL, share certificate(s) representing such number of Rights Shares will be sent by ordinary post, at their own risk, to their mailing addresses in Singapore as maintained with the Share Registrar, within ten (10) Market Days after the Closing Date.

<sup>(1)</sup> Rounded to the nearest decimal place.

# 2.4 Sale of Nil-Paid Rights of Foreign Shareholders

The Company has not sold any of the 47,463,104 provisional allotments of Rights Shares which would otherwise have been provisionally allotted to Foreign Shareholders. The Rights Shares represented by such provisional allotments shall be utilised to satisfy the Excess Applications, disposed of or dealt with in such manner as the Board may, in their absolute discretion, deem fit in the interests of the Company and no Foreign Shareholder or persons acting to the account or benefit of any such persons shall have any claim whatsoever against the Company, the Directors, the Sponsor, CDP, the Share Registrar and/or their respective officers in connection therewith.

### 3. Results of the Irrevocable Undertakings

Pursuant to the CJ Irrevocable Undertaking, CJ had undertaken to, among others, subscribe and/or procure the subscription for fifty per cent (50%) of his *pro-rata* Rights Shares entitlement, which amounts to 77,055,100 Rights Shares.

Pursuant to the YPJ Irrevocable Undertaking, YPJ had undertaken to, among others, fully subscribe and/or procure the full subscription for his *pro-rata* Rights Shares entitlement, which amounts to 55,370,554 Rights Shares.

Pursuant to the LSHL Irrevocable Undertaking, LSHL had undertaken to, among others, fully subscribe and/or procure the full subscription for her *pro-rata* Rights Shares entitlement, which amounts to 10,000 Rights Shares and 249,990,000 Excess Rights Shares.

In furtherance of paragraph 2.2 above, LSHL, an Undertaking Shareholder, had ranked last in priority for the rounding of odd lots and allotment of Excess Rights Shares. As the aggregate valid Excess Applications (excluding LSHL's valid Excess Application) are in excess of the provisional allotments of Rights Shares allocated to satisfy the valid Excess Applications, no Excess Rights Shares has been allotted to LSHL.

Accordingly, the Undertaking Shareholders have each subscribed for the following:

- (a) CJ has subscribed for an aggregate of 77,055,100 Rights Shares;
- (b) YPJ has subscribed for an aggregate of 55,370,554 Rights Shares; and
- (c) LSHL has subscribed for an aggregate of 10,000 Rights Shares.

# 4. Refund for invalid or unsuccessful acceptances and Excess Applications, and of surplus application monies

In the case of any acceptance of the provisional allotment of Rights Shares and (if applicable) Excess Application which is invalid or unsuccessful, or if an Entitled Shareholder applies for Excess Rights Shares but no Excess Rights Shares are allotted to that Entitled Shareholder, or if the number of Excess Rights Shares allotted to that Entitled Shareholder is less than the number applied for, the amount paid on acceptance and Excess Application, or the surplus application monies, as the case may be, will be refunded to the relevant Entitled Shareholder, Purchaser or their Renouncees by the Company (in the case of Entitled Scripholders) or CDP (in the case of Entitled Depositors and Purchasers) on behalf of the Company without interest or any share of revenue or other benefit arising therefrom by any one or a combination of the following:

(a) in respect of Entitled Depositors, where the acceptance and (if applicable) application had been made through Electronic Application through an ATM of a Participating Bank or an Accepted Electronic Service, by crediting the relevant applicants' bank accounts with the relevant Participating Bank, at their own risk, with the appropriate amount within three (3) Business Days after the commencement of trading of the Rights Shares, the receipt by such bank being a good discharge by the Company and CDP of their obligations, if any;

- (b) in respect of Entitled Depositors, where the acceptance and (if applicable) application had been made through CDP, by crediting their designated bank accounts via CDP's Direct Crediting Service, at their own risk. In the event they are not subscribed to CDP's Direct Crediting Service, any monies to be paid shall be credited to their Cash Ledger and subject to the same terms and conditions as Cash Distributions under the CDP Operation of Securities Account with the Depository Terms and Conditions (Cash Ledger and Cash Distribution as defined therein), as the case may be, (in each case), at their own risk, or in such other manner as they may have agreed with CDP for the payment of any cash distributions, within three (3) Business Days after the commencement of trading of the Rights Shares; or
- in respect of Entitled Scripholders, where the acceptance and (if applicable) application had been made through the Share Registrar, by means of a crossed cheque drawn in Singapore currency on a bank in Singapore and sent to them at their mailing addresses in Singapore as maintained with the Share Registrar by ordinary post and at their own risk, within fourteen (14) days after the Closing Date.

# 5. Final Net Proceeds from the Rights Issue

- 5.1 On the close of the Rights Issue, based on the aggregate subscription of 1,239,482,704 Rights Shares, the Company raised approximately S\$2.479 million of gross proceeds from the Rights Issue. After deducting expenses of approximately S\$250,000 incurred in connection with the Rights Issue, the final net proceeds from the Rights Issue are approximately S\$2.229 million (the "Final Net Proceeds").
- 5.2 The Final Net Proceeds will be allocated and utilised by the Group as follows:

Use of Final Net Proceeds	Amount (S\$'000)	Percentage of Final Net Proceeds (%)
General working capital requirements of the	2,229	100
Group		
Total	2,229	100

- Pending the deployment of the Final Net Proceeds for the abovementioned uses, the Final Net Proceeds (or part thereof) may be deposited with financial institutions, invested in short-term money markets instruments, debt instruments and/or marketable securities, and/or used for any other purposes on a short-term basis as the Directors may, in their absolute discretion, deem appropriate in the interests of the Group.
- 5.4 The Company will make periodic announcements on the utilisation of the Final Net Proceeds as and when such proceeds are materially disbursed, and on whether such disbursements are in accordance with the stated use of proceeds. In addition, the Company will subsequently provide a status report on the use of the Final Net Proceeds in its interim and full year financial results announcement(s) and in the annual report(s) of the Company, until such time as the Final Net Proceeds have been fully utilised. Where there is any material deviation from the use of proceeds described above, the Company will announce the reasons for such deviation. Where the proceeds have been used for general corporate and/or working capital purposes, the Company

will provide a breakdown with specific details on how the proceeds have been applied in the Company's announcement(s) and its annual report(s).

# 6. Listing and quotation of the Rights Shares

- Barring any unforeseen circumstances, the Company expects that 1,239,482,704 Rights Shares will be allotted and issued on or about 10 December 2024 pursuant to the Rights Issue. The Rights Shares, when allotted and issued, will rank *pari passu* in all respects with the then existing Shares, save for any dividends, rights, allotments or other distributions, the record date for which falls before the date of issue of the Rights Shares.
- The Company also expects that the Rights Shares will be listed and quoted on the Catalist of the SGX-ST on or about 12 December 2024 and trading of such Rights Shares will commence with effect from 9:00 a.m. on 12 December 2024. The Company will release an announcement to inform Shareholders on the date of the listing of and quotation for the Rights Shares on the Catalist of the SGX-ST in due course.
- 6.3 The Board wishes to take this opportunity to thank Shareholders who have participated in the Rights Issue for their support for the Rights Issue and the Company.

# By Order of the Board

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

9 December 2024

This announcement has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "Sponsor").

This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Goh Mei Xian, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.